Search
Search Results
-
Evaluation of [11C]UCB-A positron emission tomography in human brains
BackgroundIn preclinical studies, the positron emission tomography (PET) imaging with [ 11 C]UCB-A provided promising results for imaging synaptic...
-
Assessment of cerebral drug occupancy in humans using a single PET-scan: A [11C]UCB-J PET study
PurposeHere, we evaluate a PET displacement model with a Single-step and Numerical solution in healthy individuals using the synaptic vesicle...
-
Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density
Rationale[ 11 C]-UCB-J is an emerging tool for the noninvasive measurement of synaptic vesicle density in vivo. Here, we report human biodistribution...
-
Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [11C]UCB-J PET study in a model of obsessive–compulsive disorder-like behaviour
BackgroundCurrently, the evidence on synaptic abnormalities in neuropsychiatric disorders—including obsessive–compulsive disorder (OCD)—is emerging....
-
Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A
BackgroundAntiepileptic drugs, levetiracetam (LEV) and brivaracetam (BRV), bind to synaptic vesicle glycoprotein 2A (SV2A). In their anti-seizure...
-
The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J
PurposeAging is a major societal concern due to age-related functional losses. Synapses are crucial components of neural circuits, and synaptic...
-
Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial
Selective serotonin reuptake inhibitors (SSRIs) are widely used for treating neuropsychiatric disorders. However, the exact mechanism of action and...
-
Low-grade inflammation from prenatal period to age 6–8 years in a Vitamin D trial
BackgroundLow-grade systemic inflammation measured as high sensitivity C-reactive protein (hs-CRP) has been associated with non-communicable disease...
-
Validation and test–retest repeatability performance of parametric methods for [11C]UCB-J PET
[ 11 C]UCB-J is a PET radioligand that binds to the presynaptic vesicle glycoprotein 2A. Therefore, [ 11 C]UCB-J PET may serve as an in vivo marker of...
-
The associations of psychopathology and metabolic parameters with serum bilirubin levels in patients with acute-episode and drug-free schizophrenia: a 5-year retrospective study using an electronic medical record system
BackgroundThe oxidative system plays an important role in the pathogenesis of schizophrenia. Inconsistent associations were found between...
-
Incidence trends and survival prediction of urothelial cancer of the bladder: a population-based study
BackgroundThe aim of this study is to determine the incidence trends of urothelial cancer of the bladder (UCB) and to develop a nomogram for...
-
In vivo evidence of lower synaptic vesicle density in schizophrenia
Decreased synaptic spine density has been the most consistently reported postmortem finding in schizophrenia (SCZ). A recently developed in vivo...
-
The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study
Glutamatergic excitotoxicity is hypothesised to underlie synaptic loss in schizophrenia pathogenesis, but it is unknown whether synaptic markers are...
-
A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [18F]SDM-16
PurposeTo quantify the synaptic vesicle glycoprotein 2A (SV2A) changes in the whole central nervous system (CNS) under pathophysiological conditions,...
-
Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern
Next to amyloid and tau, synaptic loss is a key pathological hallmark in Alzheimer’s disease, closely related to cognitive dysfunction and...
-
Chemoprevention of bilirubin encephalopathy with a nanoceutical agent
BackgroundTargeted rapid degradation of bilirubin has the potential to thwart incipient bilirubin encephalopathy. We investigated a novel...
-
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
The discovery of ketamine as a rapid and robust antidepressant marks the beginning of a new era in the treatment of psychiatric disorders. Ketamine...
-
Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET)
PurposeExploring synaptic density changes during brain growth is crucial to understanding brain development. Previous studies in nonhuman primates...
-
Preliminary evidence for preserved synaptic density in late-life depression
Late-life depression has been consistently associated with lower gray matter volume, the origin of which remains largely unexplained. Recent in-vivo...
-
Preclinical PET Studies of [11C]UCB-J Binding in Minipig Brain
PurposeLoss of neuronal synapse function is associated with a number of brain disorders. The [ 11 C]UCB-J positron emission tomography (PET) tracer...
